欢迎来到OAJRC平台！
登录 | 注册 | English
期刊目次
加入编委
添加您的邮件地址以接收即将发行期刊数据：
Open Access Article
International Journal of Clinical Research. 2020; 4: (1) 1; 1-6 ; DOI: DOI:10.12208/j.ijcr.20200001.
中南大学湘雅医院
*通讯作者： 詹显全,单位：中南大学湘雅医院；
国家高技术“863计划”子项目国家自然科学基金湖南省自然科学基金湖南省百人计划基金湘雅医院人才引进基金
发布时间: 2020-01-17 总浏览量: 6650
PDF 全文下载 引用本文 收录截图（CNKI-Scholar）
促性腺激素假说和二元论假说促进了人们对卵巢癌发病机制的认识，然而其分子病理机制仍不清楚，障碍了卵巢癌的早期诊断、治疗和预后评估。线粒体作为细胞能量代谢、氧化应激和细胞信号的中心，与卵巢癌的发生、发展、治疗和预后有着密切的关系。随着线粒体蛋白质组学的发展，线粒体的分离和纯化，及其蛋白质的检测、鉴定和定量均有极大改善，有利于全面深入研究卵巢癌线粒体及其功能机制，发现以线粒体为靶点的分子标志物、药物靶点，服务于卵巢癌的早期诊断和治疗，改善其预后。
The gonadotropin hypothesis and the dualism hypothesis have promoted people's understanding of the pathogenesis of ovarian cancer. However, its molecular pathological mechanism remains unclear so that hinders the early-stage diagnosis, treatment and prognostic assessment of ovarian cancer. Mitochondria, as the centers of cellular energy metabolism, oxidative stress, and cell signaling, are closely related to the occurrence, development, treatment and prognosis of ovarian cancers. With the development of mitochondrial proteomics, the isolation and purification of mitochondria, as well as the detection, identification, and quantification of proteins have been significantly improved, which are conducive to a comprehensive and in-depth study of mitochondria of ovarian cancers and its functional mechanisms, further discovering molecular biomarkers and therapeutic targets targeting mitochondria, and contributing to the early diagnosis and treatment of ovarian cancer and improving its prognosis.
[1] Choi J H, Wong A S, Huang H F, et al. Gonadotropins and ovarian cancer.Endocr Rev,2007 28 (4) : 440-461.
[2] Rzepka-Gorska I, Chudecka-Glaz A, Kosmowska B. FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary.Endocr Relat Cancer,2004 11 (2) : 315-321.
[3] Huang Y, Hua K, Zhou X, et al. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.Cell Res,2008 18 (7) : 780-791.
[4] Mertens-Walker I, Bolitho C, Baxter R C, et al. Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C-delta.Endocr Relat Cancer,2010 17 (2) : 335-349.
[5] Shih I, Kurman R J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Am J Pathol,2004 164 (5) : 1511-1518.
[6] Cho K R, Shih I. Ovarian cancer.Annu Rev Pathol,2009 4 : 287-313.
[7] Conic I, Dimov I, Tasic-Dimov D, et al. Ovarian epithelial cancer stem cells.Sci World J,2011 11 : 1243-1269.
[8] Ahmed A A, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.J Pathol,2010 221 (1) : 49-56.
[9] Dubeau L. The cell of origin of ovarian epithelial tumours.Lancet Oncol,2008 9 (12) : 1191-1197.
[10] Piek J M, van Diest P J, Zweemer R P, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.J Pathol,2001 195 (4) : 451-456.
[11] Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact.J Clin Oncol,2008 26 (32) : 5284-5293.
[12] Schlichtholz B, Turyn J, Goyke E, et al. Enhanced citrate synthase activity in human pancreatic cancer.Pancreas,2005 30 (2) : 99-104.
[13] Lu C, Venneti S, Akalin A, et al. Induction of sarcomas by mutant IDH2.Genes Dev,2013 27 (18) : 1986-1998.
[14] Gupta S C, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.Antioxid Redox Signal,2012 16 (11) : 1295-1322.
[15] Pelicano H, Lu W, Zhou Y, et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.Cancer Res,2009 69 (6) : 2375-2383.
[16] Zhang Y, Wang H, Qian Z, et al. Low-voltage-activated T-type Ca2+ channel inhibitors as new tools in the treatment of glioblastoma: the role of endostatin.Pflugers Arch,2014 466 (4) : 811-818.
[17] Gorlach A, Bertram K, Hudecova S, et al. Calcium and ROS: A mutual interplay.Redox Biol,2015 6 : 260-271.
[18] Zhang W M, Zhou J, Ye Q J. Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+.Life Sci,2008 82 (13-14) : 764-771.
[19] Raphael M, Lehen'Kyi V, Vandenberghe M, et al. TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival.Proc Natl Acad Sci U S A,2014 111 (37) : E3870-E3879.
[20] Baysal B E. Role of mitochondrial mutations in cancer.Endocr Pathol,2006 17 (3) : 203-212.
[21] Cecil Han, Lifeng Yang, Hyun Ho Choi, et al. Amplification of USP13 drives ovarian cancer metabolism.Nat Commun,2016 7 (13525) .
[22] Zhihong Ai, Yang Lu, Songbo Qiu, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.Cancer Lett,2016 373 (1) : 36-44.
[23] Zou J, Wang Y, Liu M, et al. Euxanthone inhibits glycolysis and triggers mitochondria-mediated apoptosis by targeting hexokinase 2 in epithelial ovarian cancer.Cell Biochem Funct,2018 36 (6) : 303-311.
[24] Lu Xu, Qi Xie, Ling Qi, et al. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep,2019 39 (3) : 985-992.
[25] Stimpson S E, Coorssen J R, Myers S J. Optimal isolation of mitochondria for proteomic analyses.Anal Biochem,2015 475 : 1-3.
[26] Hartwig S, Feckler C, Lehr S, et al. A critical comparison between two classical and a kit-based method for mitochondria isolation.Proteomics,2009 9 (11) : 3209-3214.
[27] Song G, Hu C, Zhu H, et al. Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model.BMC Gastroenterol,2013 13 : 64.
[28] Scheffler N K, Miller S W, Carroll A K, et al. Two-dimensional electrophoresis and mass spectrometric identification of mitochondrial proteins from an SH-SY5Y neuroblastoma cell line.Mitochondrion,2001 1 (2) : 161-179.
[29] Wittig I, Carrozzo R, Santorelli F M, et al. Supercomplexes and subcomplexes of mitochondrial oxidative phosphorylation.Biochim Biophys Acta,2006 1757 (9-10) : 1066-1072.
[30] Taylor S W, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome.Nat Biotechnol,2003 21 (3) : 281-286.
[31] Techritz S, Lutzkendorf S, Bazant E, et al. Quantitative and qualitative 2D electrophoretic analysis of differentially expressed mitochondrial proteins from five mouse organs.Proteomics,2013 13 (1) : 179-195.
[32] Ferreira R, Vitorino R, Alves R M, et al. Subsarcolemmal and intermyofibrillar mitochondria proteome differences disclose functional specializations in skeletal muscle.Proteomics,2010 10 (17) : 3142-3154.
[33] Song G, Hu C, Zhu H, et al. Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model.BMC Gastroenterol,2013 13 : 64.
[34] Techritz S, Lutzkendorf S, Bazant E, et al. Quantitative and qualitative 2D electrophoretic analysis of differentially expressed mitochondrial proteins from five mouse organs.Proteomics,2013 13 (1) : 179-195.
[35] Tian Y, Tan A C, Sun X, et al. Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance.Proteomics Clin Appl,2009 3 (11) : 1288-1295.
[36] Chen X, Wei S, Ma Y, et al. Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.Theranostics,2014 4 (12) : 1164-1175.
[37] Chen M, Huang H, He H, et al. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.Cancer Sci,2015 106 (8) : 1075-1083.
入驻平台
回到首页
扫一扫，添加我们